Metyrapone as Additive Treatment in Major Depression

Authors:
  • MSMildred Schick
    Mildred Schick
  • FKFalk Kiefer
    Falk Kiefer
  • MKMichael Kellner
    Michael Kellner
  • AYAlexander Yassouridis
    Alexander Yassouridis
  • KWKlaus Wiedemann
    Klaus Wiedemann

Abstract
Our understanding of the neuroendocrine pathophysiology of depressionhas made significant progress in recent years, which should help to developnew remedies. Alterations of the hypothalamic-pituitary-adrenal (HPA) axisare the most consistent pathological endocrine findings in depression.1-3 The key regulator ofHPA axis activity, corticotropin-releasing hormone (CRH), is increased indepression.4-6 Theeffects of CRH are modulated by neuropeptides7-9 andmonoaminergic transmitters.10,11 Theexaggerated HPA function in depression appears to be also the result of animpaired glucocorticoid receptor (GR)12,13 andmineralocorticoid receptor (MR)14,15 feedbackcontrol. Whether HPA-axis hyperactivity is initially caused by a CRH overdriveresulting in MR/GR dysfunction or vice versa by dysregulation at another levelis yet undecided.16,17

This publication has 17 references indexed in Scilit: